Veeva Systems is executing strongly, with accelerating growth in Vault CRM migrations and robust momentum across its portfolio, supporting my continued buy rating. Crossix is a standout growth driver, expanding rapidly and delivering measurable ROI for customers, making it a high-priority investment for pharma clients. Veeva's targeted AI strategy, embedding AI agents into core workflows, positions the company for deeper integration and future monetization opportunities.
Veeva Systems (VEEV) reached $281 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.
Veeva's new AI layer in Vault boosts automation and deepens pharma reliance, sharpening its edge in life sciences tech.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Veeva (VEEV) reported earnings 30 days ago. What's next for the stock?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Veeva (VEEV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Veeva (VEEV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
After reaching an important support level, Veeva Systems (VEEV) could be a good stock pick from a technical perspective. VEEV surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Veeva Systems delivered a standout quarter, raising guidance and demonstrating accelerating growth, with Crossix and the company's Commercial Cloud, overall, driving strong revenue and margin outperformance. Despite macro and competitive risks, I see Veeva's competitive position strengthening, especially as migrations to Vault CRM and new AI offerings gain traction. Veeva AI, launching in December, is poised to boost growth and productivity, supporting my increased 3-year CAGR estimate to 20% and justifying the premium valuation.
Veeva Systems launches China Campaign Manager to boost pharma engagement with localized, compliant CRM-driven solutions.
Veeva (VEEV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.